

-17% MNTR Gain since Cancer Immunotherapy Announcement at \$1.01/sh on 7/10/09

Now at: **\$0.84**

Annualized MNTR Gain: **-15%**

49% Index Gain / 60

Cancer Immunotherapy Index*

Annualized Index Gain: **42%**

35% Versus Gain / 60 wks for (NASDAQ:Biotech + S&P Biotech + NYSE Biotech Indices) / 3

Annualized Average of 3 Indices Gain: **31%**

Company in CI Index	Symbol	3-Sep Price	10-Jul-09 Start Price	60 week Gain	Market Cap	Cash Eq per Sh	USA Market for Cancer Types	MKT / Mkt Cap
Quantum Immunologics, Inc. (Breast Cancer & OFA / iLRP Universally Expressed on All Cancers Tested)	(Private)	\$16.00	\$12.00	33%	\$30 M	\$0.42	\$25.9 B	853 x
Dendreon Corporation (Prostate, Breast, Colon, Ovarian, Lung & Kidney Cancers & Monoclonal AB)	(DNDN)	\$40.87	\$23.06	77%	\$5,482 M	\$4.30	\$20.4 B	4 x
Oncothyreon (Lung Cancer)	(ONTY)	\$3.56	\$3.12	14%	\$91 M	\$0.75	\$5.2 B	57 x
Antigenics (Brain Cancers)	(AGEN)	\$0.79	\$1.53	-49%	\$71 M	\$0.26	\$0.3 B	4 x
Biovest International (Non-Hodgkins Lymphoma)	(BVTI.OB)	\$1.05	\$0.35	200%	\$101 M	\$0.00	\$1.9 B	19 x
Celldex Therapeutics, Inc. (Brain Cancer & Monoclonal Antibodies)	(CLDX)	\$3.53	\$7.10	-50%	\$112 M	\$2.60	\$5.8 B	52 x
ImmunoCellular Therapeutics, Ltd. (Peptide Based & Stem Cell)	(IMUC.OB)	\$1.00	\$0.30	233%	\$16 M	\$0.09	\$16.7 B	1,041 x
Northwest Biotherapeutics, Inc. (Prostate, Brain, Lung & Ovarian Cancers)	(NWBO.OB)	\$1.03	\$0.75	37%	\$60 M	\$0.00	\$7.2 B	121 x
CEL-SCI Corporation (Head and Neck Cancers & Cytokines)	(CVM)	\$0.50	\$0.40	26%	\$102 M	\$0.16	\$3.4 B	34 x
Generex Biotechnology Corporation (Breast & Prostate Cancers)	(GNBT)	\$0.41	\$0.55	-26%	\$104 M	\$0.06	\$2.3 B	22 x
Provectus Pharmaceuticals, Inc. (Melanoma)	(PVCT.OB)	\$0.95	\$1.04 <small>(Added 2-22-10)</small>	-9%	\$67 M	\$0.05	\$0.8 B	12 x
CANCER IMMUNOTHERAPY INDEX (\$1,000 Total - Invested Equally at Index Start-up on July 10, 2009)		\$1,486	\$1,000	49%	\$6,237 M	20%	\$90.0 B ***	14 x

* Cancer Immunotherapy Index was developed with Mike Havrilla, PhD., Editor of MikeHavRx.com, initially as a sub-set to his Cancer Diagnostic & Therapeutic Micro-Cap Index.

** 33.3% gain reflects MNTR private bids at \$16 and matches corresponding 33.66% gain by MNTR during 22 week period in which MNTR substantially held only QI.

*** Market Data from National Cancer Institute based on Relative Mortality in company treatment areas with market shared by all participating companies in their treatment areas.

NO INVESTMENT ADVISORY DISCLAIMER: Readers are cautioned that Mentor Capital, Inc. does not intend this Cancer Immunotherapy Index to be investment advice. The CI Index is a mathematical, information only index and has been published on a regular weekly basis since inception. The original and continuing purpose is to establish a benchmark as to how the cancer immunotherapy sector as a whole has behaved. As such, it presents historic information and does not purport nor imply any opinion or advice on the current or future value of any stock, nor account for trading costs that in practice will reduce investment gains. Always consult with your investment advisor before buying MNTR or CI Index stocks.